- Faculty
- Health
- In the News
PhII Study of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma
Daniela Bota
A Study On:
- Brain and Nervous System
Status:
- Open
Eligibility
Adults
Interested in joining this trial?
Official Title
An Open-Label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinectics of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma (PCNSL)
Details
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolimide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)
Eligibility
You can join if...
Inclusion Criteria:
- Pathologically diagnosed with Primary Central Nervous System Lymphoma
- Life expectancy of at least 3 months (part A) or at least 6 months (part B)
- Adequate bone marrow, renal, and hepatic function as described by the study protocol
Exclusion Criteria:
- Patient who is intolerant of contrast-enhanced MRI due to allergic reactions to contrast agents
- Patient with systemic presence of lymphoma
- Prior radiotherapy within 14 days before starting tirabrutinib (study drug) treatment
Get in touch with our study team
News & Events
UCI Health enrolls patient in first U.S. study of medical device for erectile dysfunction Sickle cell disease treatment nearing FDA approval - Faculty
- Health
- In the News
His GERD is now a distant memory - Faculty
- Health
- In the News